Poor outcome of myeloablative conditioned allogeneic bone marrow transplantation for myelofibrosis.
OBJECTIVE
This study retrospectively analyzed clinical outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelofibrosis (MF) in a single institution.


METHODS
During the past 20 years, 6 patients with MF have undergone allo-HSCT in our institution. We investigated the clinical characteristics and follow-up course of these patients.


METHODS
Median age was 47 years (range, 40-52 years). The median interval between diagnosis and allo-HSCT was 12.5 months (range, 5-97 months).


RESULTS
Among these 6 patients, 4 patients were categorized in the high-risk group according to the International Prognostic Scoring System. All 6 patients received myeloablative conditioning regimens, but most of them eventually died of relapse.


CONCLUSIONS
In this small series, allo-HSCT resulted in dismal outcomes. Our experience clearly indicates the need for studies with a larger series of patients to evaluate the efficacy of this modality.
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan.
Masahide
M
Yamamoto
Kazuteru
K
Ohashi
Yuka
Y
Hirashima
Takeshi
T
Kobayashi
Kazuhiko
K
Kakihana
Hideki
H
Akiyama
Hisashi
H
Sakamaki
D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome